Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled study of inhaled ciprofloxacin DPI in non-cystic fibrosis bronchiectasis
2011-004208-39Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ciprofloxacin in bronchiectasis (3 arms), sponsored by Bayer. Primary endpoints: Time to first exacerbation and Frequency of exacerbations. Started Oct 2012; status: completed.
02
Drugs
ciprofloxacin
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2011-004208-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004208-39.